Asthma Patents (Class 514/826)
  • Patent number: 9034846
    Abstract: The invention provides the use of a cyclodextrin compound for the manufacturing of a medicament for the treatment or prevention of bronchial inflammatory diseases, particularly for asthma and chronic obstructive pulmonary disease (COPD).
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: May 19, 2015
    Assignee: UNIVERSITE DE LIEGE
    Inventors: Didier Cataldo, Brigitte Evrard, Agnes Noel, Jean-Michel Foldart
  • Patent number: 9023402
    Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: May 5, 2015
    Assignee: ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda.
    Inventors: Werner E. Haas, Carlos C. Romao, Beatriz Royo, Ana Cristina Fernandes, Isabel Goncalves
  • Patent number: 8993640
    Abstract: The present invention relates generally to the compound: N-((4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropanamide, polymorphic forms thereof, methods for preparation and use thereof, pharmaceutical compositions thereof, and kits and articles of manufacture thereof.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: March 31, 2015
    Assignee: Reata Pharmaceuticals, Inc.
    Inventors: Eric Anderson, Xiaofeng Liu, Andrea Decker
  • Patent number: 8852588
    Abstract: Treatment of an allergic airway disorder (e.g., asthma or bronchial airway obstruction) using anti-IL-20R1 antibodies such as mAb51D, mAb7GW, or functional variants thereof.
    Type: Grant
    Filed: August 7, 2012
    Date of Patent: October 7, 2014
    Assignee: National Cheng Kung University
    Inventor: Ming-Shi Chang
  • Patent number: 8802699
    Abstract: Provided is a pharmaceutical composition comprising: (i) 3-(2-hydroxy-2,2-dithien-2- ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo-[2.2.2]octane or an enantiomer, mixture of enantiomers, or a racemate thereof, wherein an anion X?with a single negative charge is associated with the positive charge of the nitrogen atom; and (ii) a phosphodiesterase IV inhibitor and methods of using the same.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: August 12, 2014
    Assignee: Almirall, S.A.
    Inventors: Maria Dolors Fernandez Forner, Maria Prat Quinones, Maria Antonia Buil Albero
  • Patent number: 8796333
    Abstract: Disclosed are methods of treating an individual having a condition characterized by an imbalance in type 1 and type 2 cytokine production, wherein the method comprises administering to the individual an amount of ?-hydroxy-?-methylbutyrate (HMB) effective to modulate or otherwise cause an increase in the ratio of type 1 to type 2 cytokines, including an increase in the ratio of type 1 to type 2 cytokines without a corresponding increase in type 2 cytokine levels. Also disclosed are methods of using HMB to treat asthma and allergies. The methods of the present invention are based upon the discovery that HMB modulates cytokine production, most typically by increasing type 1 cytokines without a corresponding increase in type 2 cytokines.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: August 5, 2014
    Assignee: Abbott Laboratories
    Inventors: Debra L. Thomas, Pradip Mukerji
  • Patent number: 8778992
    Abstract: Disclosed are methods of treating an individual having a condition characterized by an imbalance in type 1 and type 2 cytokine production, wherein the method comprises administering to the individual an amount of ?-hydroxy-?-methylbutyrate (HMB) effective to modulate or otherwise cause an increase in the ratio of type 1 to type 2 cytokines, including an increase in the ratio of type 1 to type 2 cytokines without a corresponding increase in type 2 cytokine levels. Also disclosed are methods of using HMB to treat asthma and allergies. The methods of the present invention are based upon the discovery that HMB modulates cytokine production, most typically by increasing type 1 cytokines without a corresponding increase in type 2 cytokines.
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: July 15, 2014
    Assignee: Abbott Laboratories
    Inventors: Debra L. Thomas, Pradip Mukerji
  • Patent number: 8703754
    Abstract: The present invention relates to a compound which is 6-amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one: in the form of a maleate salt, may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases and cancer, and may also be useful as vaccine adjuvants.
    Type: Grant
    Filed: February 8, 2011
    Date of Patent: April 22, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: Robert Hermann Gibbon, Amanda Lucas, Stephen Andrew Hermitage
  • Patent number: 8546358
    Abstract: The present invention is directed to a method for treating or ameliorating asthma in a subject in need thereof comprising administering to the subject a therapeutically effective amount of compound 17:
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: October 1, 2013
    Assignee: Janssen Pharmaceutica NV
    Inventors: Michael J. Hawkins, Michael N. Greco, Eugene Powell, Lawrence de Garavilla, Bruce E. Maryanoff
  • Patent number: 8513279
    Abstract: The invention provides 3-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide in combination with a steroid, and methods of using it for treatment of respiratory disorders.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: August 20, 2013
    Assignee: Almirall, S.A.
    Inventors: Maria Dolors Fernandez Forner, Maria Prat Quinones, Maria Antonia Buil Albero
  • Patent number: 8454938
    Abstract: A method for treating a mammal suffering from a respiratory disease characterized by acute intermittent or chronic obstruction of the airways of the lungs, such as asthma, acute asthma, chronic obstructive pulmonary disease (COPD) and bronchiectasis comprising delivering to the lungs of the mammal a perfluorocarbon and a gas mixture comprising carbon dioxide (CO2), and pharmaceutical compositions of CO2 and perfluorocarbons are provided. The acute relief of airway obstruction provided by the said treatment provides an opportunity for concomitant or subsequent delivery of additional suitable active agent of conventional treatments.
    Type: Grant
    Filed: December 21, 2006
    Date of Patent: June 4, 2013
    Assignee: Solaeromed Inc.
    Inventors: Francis H. Y. Green, Tamer Y. El Mays, Samuel Schurch
  • Patent number: 8399416
    Abstract: The present invention is for an isolated peptide consisting of the amino acid sequence of SEQ ID NO: 9 and using the peptide for treating asthma by reducing cytotoxicity of eosinophil derived toxins in bronchial epithelial cells of the subject suffers from asthma. The method comprises preparing a pharmaceutical composition having the peptide of SEQ ID NO: 9 and administering an effective amount of the composition to the subject.
    Type: Grant
    Filed: February 27, 2012
    Date of Patent: March 19, 2013
    Assignee: National Tsing Hua University
    Inventors: Margaret Dah-Tsyr Chang, Tan-chi Fan, Shu-Chuan Lin
  • Patent number: 8349897
    Abstract: The invention relates to substituted phenoxyacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: January 8, 2013
    Assignee: Astrazeneca AB
    Inventors: Timothy Jon Luker, Rukhsana Tanseem Mohammed, Mark Dickinson, Stephen Thom
  • Patent number: 8293796
    Abstract: The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein Z is OR1 or NR1R2 wherein each of R1 and R2 is independently H, or a hydrocarbyl group; X is an alkylene, alkenylene, or alkynylene group, each of which may be optionally substituted by one or more substituents selected from alkyl, COOH, CO2-alkyl, alkenyl, CN, NH2, hydroxy, halo, alkoxy, CF3 and nitro; Y is a polar functional group selected from OH, NO2, CN, COR3, COOR3, NR3R4, CONR3R4, SO3H, SO2—R3, SO2NR3R4 and CF3, where each of R3 and R4 is independently H or a hydrocarbyl group; A is an aryl or heteroaryl group, each of which may be optionally substituted; and B is (CH2)n where n is 0, 1, 2, 3, 4 or 5; with the proviso that: (i) when A is phenyl, n is 0, and Z is OH, X—Y is other than meta-C?—C—(CH2)2CO2H, meta-C?—C—(CH2)2OH, meta-C?C—(CH2)2CO2Me, meta-(CH2)4CO2H, ortho-CH2CO2H, ortho-(CH2)2CO2H and ortho-(CH2)4CO2H; and (ii) when A is phenyl, n is 0, and Z is OMe, X—Y is other than meta-C?
    Type: Grant
    Filed: February 18, 2010
    Date of Patent: October 23, 2012
    Assignee: University College London
    Inventors: Masahiro Okuyama, David Selwood, Cristina Visintin, David Baker, Gareth Pryce
  • Patent number: 8268331
    Abstract: The invention provides gp38 polypeptides, which play a role in immunomodulation, nucleic acid molecules encoding these polypeptides, and therapeutic and diagnostic methods employing these polypeptides and nucleic acid molecules. The invention also provides methods for identifying compounds that modulate the biological activities of gp38 nucleic acid molecules and polypeptides, and therapeutic methods employing these compounds.
    Type: Grant
    Filed: May 7, 2009
    Date of Patent: September 18, 2012
    Assignee: Viron Therapeutics, Inc.
    Inventors: Grant McFadden, Karim Essani
  • Patent number: 8168678
    Abstract: Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGD2 receptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.
    Type: Grant
    Filed: January 29, 2009
    Date of Patent: May 1, 2012
    Assignee: Panmira Pharmaceuticals, Inc.
    Inventors: John Howard Hutchinson, Brian Andrew Stearns, Yen Pham Truong
  • Patent number: 8138158
    Abstract: Compositions and methods for therapy of cystic fibrosis, asthma, and other conditions characterized by defective chloride transport are provided. The compositions comprise one or more compounds such as flavones and/or isoflavones, ascorbate and/or derivatives thereof capable of stimulating chloride transport in epithelial tissues. Therapeutic methods involve the administration (e.g., orally or via inhalation) of such compositions to a patient afflicted with cystic fibrosis, asthma, and/or another condition responsive to stimulation of chloride transport.
    Type: Grant
    Filed: March 11, 2010
    Date of Patent: March 20, 2012
    Assignee: Children's Hospital & Research Center at Oakland
    Inventors: Horst Fischer, Beate Illek
  • Patent number: 8128909
    Abstract: Disclosed is a process for the preparation of sterile aqueous suspensions based on active ingredients in the form of micronised crystalline particles designed for administration by inhalation. In particular, a process for the preparation of sterile aqueous suspensions based on pharmaceutical active ingredients in the form of crystalline hydrates is disclosed.
    Type: Grant
    Filed: December 17, 2003
    Date of Patent: March 6, 2012
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Andrea Capocchi, Fausto Pivetti
  • Patent number: 8129405
    Abstract: The invention provides 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide in powder inhalant form, and methods of using it for treatment of respiratory disorders.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: March 6, 2012
    Assignee: Almirall Prodesfarma S.A.
    Inventors: Maria Dolors Fernandez Forner, Maria Prat Quiñones, María Antonia Buil Albero
  • Patent number: 8097605
    Abstract: The present invention relates to a combination of an inhaled/oral PDE 4 inhibitor in combination with inhaled anticholinergic bronchodilators (muscarinic receptor antagonists), preferentially Roflumilast or AWD-12-281 and R,R-glycopyrrolate, for symptomatic or prophylactic treatment of respiratory diseases, especially those accompanied by obstruction or inflammation such as chronic obstructive pulmonary disease (COPD) or asthma. It further comprises the presentation of this combination in a locally applied (inhaled) formulation and application in an inhalation device for instance in the Novolizer®.
    Type: Grant
    Filed: February 3, 2009
    Date of Patent: January 17, 2012
    Assignee: Meda Pharma GmbH & Co. KG
    Inventors: Joachim Maus, Peter Juergen Cnota, Istvan Szelenyi, Beatrix Fyrnys
  • Patent number: 8080540
    Abstract: Estratrien-triazoles corresponding to formula (I) (shown below) which are useful in therapy, especially for the treatment and/or prevention or inhibition of a steroid hormone dependent disorder, preferably a steroid hormone dependent disease or disorder requiring the inhibition of a 17?-hydroxysteroid dehydrogenase (17?-HSD) such as 17?-HSD type 1, type 2 or type 3 enzyme.
    Type: Grant
    Filed: September 18, 2007
    Date of Patent: December 20, 2011
    Assignee: Abbott Products GmbH
    Inventors: Josef Messinger, Uwe Schoen, Heinrich-Hubert Thole, Bettina Husen, Pasi Koskimies, Lila Kallio nee Pirkkala
  • Patent number: 8062627
    Abstract: A method and composition are disclosed utilizing the pure (R,R) isomer of formoterol, which is a potent bronchodilator with reduced adverse effects, a low incidence of the development of tolerance and an increased duration of action, as compared to racemic formoterol.
    Type: Grant
    Filed: March 13, 2008
    Date of Patent: November 22, 2011
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Gunnar Aberg, John Morley
  • Patent number: 8029768
    Abstract: A pharmaceutical composition for pulmonary delivery comprises glycopyrrolate in a controlled release formulation, wherein, on administration, the glycopyrrolate exerts its pharmacological effect over a period greater than 12 hours.
    Type: Grant
    Filed: March 14, 2008
    Date of Patent: October 4, 2011
    Assignee: Sosei R&D Ltd.
    Inventors: Robin Mark Bannister, Andrew John McGlashan Richards, Julian Clive Gilbert, David A. V. Morton, John Staniforth
  • Patent number: 8012472
    Abstract: The present invention relates to the ability of anti-Fc?R antibodies to suppress fibrocytes. Methods and compositions for suppressing fibrocytes are provided. These methods are useful in a variety of applications including treatment and prevention of conditions resulting from fibrosis in the liver, kidney, lung, heart and pericardium, eye, skin, mouth, pancreas, gastrointestinal tract, brain, breast, bone marrow, bone, genitourinary system, a tumor, or a wound.
    Type: Grant
    Filed: September 27, 2006
    Date of Patent: September 6, 2011
    Assignee: William Marsh Rice University
    Inventors: Richard Gomer, Darrell Pilling
  • Patent number: 8012508
    Abstract: The present invention relates to method of targeting therapeutic agents for treating lung diseases.
    Type: Grant
    Filed: January 15, 2008
    Date of Patent: September 6, 2011
    Assignee: Abbott Cardiovascular Systems Inc.
    Inventor: Florian N. Ludwig
  • Patent number: 8008313
    Abstract: Methods for treating respiratory and gastrointestinal diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Grant
    Filed: August 25, 2006
    Date of Patent: August 30, 2011
    Assignee: Roche Palo Alto LLC
    Inventors: Chris Allen Broka, David Scott Carter, Michael Patrick Dillon, Anthony P. D. W. Ford, Ronald Charles Hawley, Alam Jahangir, Amy Geraldine Moore, Daniel Warren Parish
  • Patent number: 7999010
    Abstract: Compounds of formula (Ia): wherein R1, R2, R3, R4a, R4b, R5 and R6 are defined herein, as well as other indene derivatives are disclosed herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
    Type: Grant
    Filed: February 23, 2010
    Date of Patent: August 16, 2011
    Assignee: Aquinox Pharmaceuticals Inc.
    Inventors: Jeffery R. Raymond, Kang Han, Yuanlin Zhou, Yuehua He, Bradley Noren, James Gee Ken Yee
  • Patent number: 7964220
    Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.
    Type: Grant
    Filed: June 14, 2006
    Date of Patent: June 21, 2011
    Assignee: ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda.
    Inventors: Werner E. Haas, Carlos C. Romao, Beatriz Royo, Ana Cristina Fernandes, Isabel Goncalves
  • Patent number: 7935343
    Abstract: Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralize IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
    Type: Grant
    Filed: July 15, 2004
    Date of Patent: May 3, 2011
    Assignee: MedImmune Limited
    Inventors: Phillip David Monk, Lutz Ulrich Jochen Jermutus, Ralph Raymond Minter, Celia Patricia Shorrock
  • Patent number: 7897617
    Abstract: The invention provides 3-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2] octane in salt form, pharmaceutical compositions comprising it, and methods of using it for treatment of respiratory disorders, in association with steroids.
    Type: Grant
    Filed: May 26, 2010
    Date of Patent: March 1, 2011
    Assignee: Almirall Prodesfarma S.A.
    Inventors: Maria Dolors Fernandez Forner, Maria Prat Quiñones, Maria Antonia Buil Albero
  • Patent number: 7829550
    Abstract: The invention provides the use of a cyclodextrin compound for the manufacturing of a medicament for the treatment or prevention of bronchial inflammatory diseases, particularly for asthma.
    Type: Grant
    Filed: September 30, 2005
    Date of Patent: November 9, 2010
    Assignee: Universite de Liege
    Inventors: Didier Cataldo, Brigitte Evrard, Agnès Noel, Jean-Michel Foidart
  • Patent number: 7815909
    Abstract: The present invention relates to inhibiting TNF in patients having rheumatoid arthritis, psoriatic arthritis or ankylosing spondilitis, by administering anti-TNF antibodies comprising the heavy chain variable region of SEQ ID NO: 7 and the light chain variable region of SEQ ID NO:8, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof.
    Type: Grant
    Filed: November 13, 2008
    Date of Patent: October 19, 2010
    Assignee: Centocor, Inc.
    Inventors: George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallon, David Shealy
  • Patent number: 7816374
    Abstract: A therapeutic method is provided to treat neutrophil-associated pulmonary diseases, such as chronic obstructive pulmonary disease, by locally administering to a mammal in need of such treatment, an effective amount of a topical anesthetic, such as lidocaine, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 8, 2008
    Date of Patent: October 19, 2010
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Gerald J. Gleich, Loren W. Hunt, Jr.
  • Patent number: 7763286
    Abstract: The present invention relates to a composition comprising an extract of Tiarella polyphylla, and tiarellic acid isolated therefrom having anti-inflammatory, anti-allergic and anti-asthmatic activity. The extract of Tiarella polyphylla and the tiarellic acid isolated therefrom shows the inhibitory effect on the LTC4 release in vitro test and the suppressive effect on the IgE level and the cytokine (IL-4, IL-5 and IL-13) production, airway hyperresponsiveness, and leukocyte infiltration in OVA-induced asthmatic mice. Therefore, it can be used as the therapeutics or functional health food for treating and preventing inflammatory, allergic and asthmatic disease.
    Type: Grant
    Filed: July 18, 2006
    Date of Patent: July 27, 2010
    Assignee: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Hyeong Kyu Lee, Sei Ryang Oh, Kyung Seop Ahn, Joong Ku Lee, Sang Ku Lee, Jung Hee Kim, Doo Young Kim, Gui Hua Quan, Ok Kyoung Kwon, Eun Ah Kim, Soon Ja Choi, Guang Hai Shen, Mi Jin Kim, Bo Young Park, Byung Sun Min, Gyoon Hee Han, Hea Young Park, Gun Cheol Kim, Joo Heon Kim, So Young Kim
  • Patent number: 7750023
    Abstract: The invention provides 3-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane in salt form, pharmaceutical compositions comprising it, and methods of using it for treatment of respiratory disorders, in association with ?2 agonist.
    Type: Grant
    Filed: March 7, 2008
    Date of Patent: July 6, 2010
    Inventors: María Dolors Fernandez Forner, María Prat Quiñones, María Antonia Buil Albero
  • Patent number: 7741292
    Abstract: A method of inhibiting the emigration of cells from the intravascular compartment into tissues (or through any membrane limiting any body compartment from another) by confronting the cells with an agonist specific for receptors involved with migration of said cells via a receptor thereby making the cell unresponsive to further activation.
    Type: Grant
    Filed: February 20, 2008
    Date of Patent: June 22, 2010
    Assignee: IPF Pharmaceuticals GmbH
    Inventors: Ulf Forssmann, Jörn Elsner, Sylvia Escher, Nikolaj Spodsberg
  • Patent number: 7718694
    Abstract: Compositions and methods for therapy of cystic fibrosis, asthma, and other conditions characterized by defective chloride transport are provided. The compositions comprise one or more compounds such as flavones and/or isoflavones, ascorbate and/or derivatives thereof capable of stimulating chloride transport in epithelial tissues. Therapeutic methods involve the administration (e.g., orally or via inhalation) of such compositions to a patient afflicted with cystic fibrosis, asthma, and/or another condition responsive to stimulation of chloride transport.
    Type: Grant
    Filed: January 30, 2004
    Date of Patent: May 18, 2010
    Assignee: Children's Hospital & Research Center at Oakland
    Inventors: Horst Fischer, Beate Illek
  • Patent number: 7713964
    Abstract: This invention provides methods for treating in mammals asthma and asthmatic conditions using substituted indole compounds of the general formula: and pharmaceutically acceptable salt forms thereof, and methods for using the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A2 enzymes, and for the medical treatment, prevention and inhibition of pain and inflammation.
    Type: Grant
    Filed: November 22, 2002
    Date of Patent: May 11, 2010
    Assignee: Wyeth LLC
    Inventors: John C. McKew, Steven Y. Tam, Katherine L. Lee, Lihren Chen, Paresh Thakker, Fuk-Wah Sum, Mark Behnke, Baihua Hu, James D. Clark
  • Patent number: 7666395
    Abstract: Chronic obstructive airway diseases are treated by administering an osmotically active compound such as a salt, sugar, sugar alcohol, or organic osmolyte to the afflicted airway surface. The compound may be administered as a liquid or dry powder aerosol formulation. Diseases that can be treated by the method include cystic fibrosis, chronic bronchitis, and ciliary dyskinesia. The formulations of the invention can also be used in conjunction with other active agents such as bronchodilators, sodium channel blockers, antibiotics, enzymes, or purinoceptor agonists on airway surfaces.
    Type: Grant
    Filed: November 18, 2004
    Date of Patent: February 23, 2010
    Assignee: The University of North Carolina at Chapel Hill
    Inventor: Richard C. Boucher, Jr.
  • Patent number: 7611694
    Abstract: The present invention relates to a propellant-free, aqueous aerosol formulation for anticholinergics of formula 1 wherein X? denotes an anion.
    Type: Grant
    Filed: June 15, 2006
    Date of Patent: November 3, 2009
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventor: Friedrich Schmidt
  • Patent number: 7566743
    Abstract: This invention relates to a system for and method for medical treatment of respiratory diseases. The system and method are particularly effective for the treatment of and protection from diseases associated with allergic inflammation. Suitable diseases for treatment include atopic asthma, rhinitis, sinusitis, and conjunctivitis.
    Type: Grant
    Filed: November 18, 2005
    Date of Patent: July 28, 2009
    Inventor: Mark Glazman
  • Patent number: 7534438
    Abstract: Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. The composition contains a protein or peptide containing a thioredoxin active-site in reduced state and optionally further contains a reducing system.
    Type: Grant
    Filed: March 2, 2007
    Date of Patent: May 19, 2009
    Assignee: National Jewish Health
    Inventor: Carl W. White
  • Patent number: 7528175
    Abstract: The use of ?-adrenergic inverse agonists provides a new and highly efficient way of treating a number of pulmonary airway diseases, including asthma, emphysema, and chronic obstructive pulmonary diseases. In general, such a method involves administering a therapeutically effective amount of a ?-adrenergic inverse agonist to the subject to treat the pulmonary airway disease. Particularly preferred inverse agonists include nadolol and carvedilol. In addition, methods are described for long-tern administration of such inverse agonists and for determining the suitability of patients for long-term inverse agonist therapy.
    Type: Grant
    Filed: October 7, 2005
    Date of Patent: May 5, 2009
    Assignee: Inverseon, Inc.
    Inventor: Richard A. Bond
  • Patent number: 7524517
    Abstract: This invention relates generally to a method of increasing cytosolic Ca2+ levels in mammalian cells comprising contacting P2X receptor Ca2+ entry channels or any and all other Ca2+ entry channels or mechanisms on the cell with an effective amount of a small molecule, and a composition comprising the small molecule in a delivery system. The invention has broad applicability in the pharmaceutical industry as a method of treating airway diseases (such as cystic fibrosis and asthma), ailments of the lung and airways (such as those caused by common cold pathogens or allergens in allergy), kidney diseases and renal hypertensive disorders (such as polycystic kidney disease and salt-sensitive hypertension syndromes), and endocrine disorders (such as diabetes).
    Type: Grant
    Filed: January 20, 2004
    Date of Patent: April 28, 2009
    Assignee: UAB Research Foundation
    Inventors: Erik Schwiebert, Akos Zsembery
  • Patent number: 7521068
    Abstract: There invention discloses aqueous dispersions of nanoparticulate aerosol formulations, dry powder nanoparticulate aerosol formulation, propellant-based aerosol formulations, methods of using the formulations in aerosol delivery devices, and methods of making such formulations. The nanoparticles of the aqueous dispersions or dry powder formulations comprise insoluble drug particles having a surface modifier on the surface thereof.
    Type: Grant
    Filed: November 12, 1998
    Date of Patent: April 21, 2009
    Assignee: Elan Pharma International Ltd.
    Inventors: H. William Bosch, Kevin D. Ostrander, Eugene R. Cooper
  • Patent number: 7521438
    Abstract: The invention relates to a novel combination of a soft steroid, in particular loteprednol, and at least one ?2 adrenoceptor agonist for the simultaneous, sequential or separate treatment of allergies and/or airway disorders, medicaments comprising the combination, processes for the production of such medicaments and the use of the novel combination for the production of medicaments for the simultaneous, sequential or separate treatment of allergies and/or airway disorders.
    Type: Grant
    Filed: September 26, 2000
    Date of Patent: April 21, 2009
    Assignee: MEDA Pharma GmbH & Co. KG
    Inventors: Istvan Szelenyi, Hildegard Kuss, Sabine Heer, Juergen Engel
  • Patent number: 7476380
    Abstract: The invention describes a means for the treatment of diseases of the tracheo-bronchial tract, particularly of COPD.
    Type: Grant
    Filed: May 12, 2005
    Date of Patent: January 13, 2009
    Assignee: GSE-Forschungszentrum fur Umwelt und Gesundheit GmbH
    Inventors: Marion Frankenberger, Konrad Maier, Gerhard Scheuch, Hans-Werner Ziegler-Heitbrock
  • Patent number: 7470422
    Abstract: The present invention relates to pharmaceutical preparations in the form of aqueous solutions for the production of propellant-free aerosols.
    Type: Grant
    Filed: August 17, 2006
    Date of Patent: December 30, 2008
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Bernhard Freund, Bernd Zierenberg
  • Patent number: 7431916
    Abstract: A method of administering a metered dry powder combined dose of finely divided dry medication powders is disclosed, wherein said method comprises providing a relative motion between a nozzle of a dry powder inhaler and a dose bed carrying said combined dose of finely divided dry medication powder intended for delivery by the dry powder inhaler, the combined dose comprises metered quantities of at least two medicaments separately deposited on the dose bed, the relative motion causing the nozzle to pass over the combined dose for a simultaneous or sequential delivery of the medicaments during the course of a single suction of air.
    Type: Grant
    Filed: June 26, 2003
    Date of Patent: October 7, 2008
    Assignee: Mederio AG
    Inventors: Thomas Nilsson, Mattias Myrman, Claes Friberg, Sven Calander
  • Patent number: 7390796
    Abstract: Compounds are disclosed of the formula in which R3 is C8 to C24 hydrocarbon or the residue of misoprostol. The compounds are useful for treating rhinitis and asthma, particularly by inhalation, and for treating inflammation, particularly by local or topical administration.
    Type: Grant
    Filed: November 14, 2006
    Date of Patent: June 24, 2008
    Assignee: Sepracor Inc.
    Inventors: Mark G. Currie, Steven Jones, Charles M. Zepp